Fri. 10 May 2024, 5:09pm ET
Benzinga
Earnings, Earnings Beats, News
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3.53) by 42.78 percent. This is a 51.9 percent increase over losses of $(4.20) per share from the same period last year.